RU2021107754A - ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА - Google Patents

ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА Download PDF

Info

Publication number
RU2021107754A
RU2021107754A RU2021107754A RU2021107754A RU2021107754A RU 2021107754 A RU2021107754 A RU 2021107754A RU 2021107754 A RU2021107754 A RU 2021107754A RU 2021107754 A RU2021107754 A RU 2021107754A RU 2021107754 A RU2021107754 A RU 2021107754A
Authority
RU
Russia
Prior art keywords
compound
cancer
hydrogen
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2021107754A
Other languages
English (en)
Inventor
Дэвид К. МАЙЛЗ
Питер Дж. КАШНЕР
Сайрус Л. ХАРМОН
Original Assignee
Олема Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олема Фармасьютикалз, Инк. filed Critical Олема Фармасьютикалз, Инк.
Publication of RU2021107754A publication Critical patent/RU2021107754A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (39)

1. Способ предотвращения рецидива рака у пациента, включающий введение пациенту соединения Формулы I:
Figure 00000001
I
или его фармацевтически приемлемой соли,
где
X является -O-;
Y является
Figure 00000002
или
Figure 00000003
;
каждый R1 и R2 является водородом;
каждый R3 и R4 независимо выбран из водорода и галогена, и когда один из R3 или R4 является галогеном, другой из R3 или R4 является водородом;
R5 является C1-C6алкилом или C1-C6галогеналкилом;
R6 является C1-C6галогеналкилом; и
каждый R7 и R8 независимо выбран из водорода и C1-C6алкила.
2. Способ по п. 1, где рак выбран из рака молочной железы, рака яичника, рака эндометрия, рака влагалища, рака легкого, рака кости, рака матки и эндометриоза.
3. Способ по п. 1, где соединение вводят в качестве вспомогательной терапии после или вместо химиотерапии, радиации или хирургии.
4. Способ по п. 3, где соединение вводят после хирургии.
5. Способ по п. 1, где соединение вводят до хирургии.
6. Способ по п. 2, где раком является рак молочной железы.
7. Способ по п. 6, где рак молочной железы прогрессировал в присутствии эндокринной терапии или терапии ингибитором ароматазы.
8. Способ по п. 1, где Y является
Figure 00000002
.
9. Способ по п. 1, где Y является
Figure 00000004
.
10. Способ по п. 1, где соединение является соединением Формулы I(a):
Figure 00000005
I(a)
или его фармацевтически приемлемой солью.
11. Способ по п. 10, где каждый R1, R2, R3 и R4 является водородом.
12. Способ по п. 1, где соединение является соединением Формулы I(c):
Figure 00000006
I(c)
или его фармацевтически приемлемой солью.
13. Способ по п. 12, где каждый R1, R2, R3 и R4 является водородом.
14. Способ по п. 1, где соединение представляет собой:
Figure 00000007
или его фармацевтически приемлемую соль.
15. Способ по п. 1, где соединение представляет собой:
Figure 00000008
или его фармацевтически приемлемую соль.
16. Способ по п. 1, где соединение представляет собой:
Figure 00000009
или его фармацевтически приемлемую соль.
RU2021107754A 2015-10-01 2016-09-29 ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА RU2021107754A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01
US62/235,900 2015-10-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018115696A Division RU2745742C1 (ru) 2015-10-01 2016-09-29 ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Publications (1)

Publication Number Publication Date
RU2021107754A true RU2021107754A (ru) 2021-04-01

Family

ID=58427985

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018115696A RU2745742C1 (ru) 2015-10-01 2016-09-29 ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
RU2021107754A RU2021107754A (ru) 2015-10-01 2016-09-29 ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2018115696A RU2745742C1 (ru) 2015-10-01 2016-09-29 ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Country Status (24)

Country Link
US (5) US10292971B2 (ru)
EP (2) EP3912680A1 (ru)
JP (3) JP6776348B2 (ru)
KR (1) KR20180071274A (ru)
CN (2) CN108366996B (ru)
AU (3) AU2016331065B2 (ru)
BR (2) BR122023020677A2 (ru)
CA (1) CA3000410A1 (ru)
CL (1) CL2018000827A1 (ru)
CY (1) CY1124669T1 (ru)
DK (1) DK3355884T3 (ru)
ES (1) ES2881398T3 (ru)
HR (1) HRP20211124T1 (ru)
HU (1) HUE055321T2 (ru)
IL (3) IL286518B1 (ru)
LT (1) LT3355884T (ru)
MX (2) MX2018003929A (ru)
PL (1) PL3355884T3 (ru)
PT (1) PT3355884T (ru)
RS (1) RS62133B1 (ru)
RU (2) RU2745742C1 (ru)
SI (1) SI3355884T1 (ru)
UA (1) UA122346C2 (ru)
WO (1) WO2017059139A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050466T2 (hu) 2014-12-18 2020-12-28 Hoffmann La Roche Tetrahidropirido[3,4-b]indolok mint ösztrogénreceptor-modulátorok és felhasználásuk
MX2018003929A (es) 2015-10-01 2018-11-22 Olema Pharmaceuticals Inc Fármacos anti-estrogénicos tetrahidro-1h-pirido [3,4-b] indol.
NZ743651A (en) 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
BR112018015419B1 (pt) * 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
ME03547B (me) 2016-10-24 2020-07-20 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu rаkа
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
MY196317A (en) 2017-01-30 2023-03-24 Astrazeneca Ab Estrogen Receptor Modulators
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的***受体降解剂
KR20230117761A (ko) 2018-06-21 2023-08-09 에프. 호프만-라 로슈 아게 3-((1R,3R)-1-(2,6-다이플루오로-4-((1-(3-플루오로프로필)아제티딘-3-일)아미노)페닐)-3-메틸-1,3,4,9-테트라하이드로-2H-피리도[3,4-b]인돌-2-일)-2,2-다이플루오로프로판-1-올의고체 형태, 치환된 페닐 또는 피리딘일 잔기를 포함하는 융합된 삼환형 화합물의 제조 방법, 및 이의 사용 방법
EP3902545A4 (en) * 2018-12-24 2022-06-22 InventisBio Co., Ltd. NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
SG11202111402PA (en) * 2019-05-14 2021-11-29 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗***受体相关疾病的方法
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
IL309986A (en) * 2021-07-08 2024-03-01 Olema Pharmaceuticals Inc Methods for treating diseases related to estrogen receptors
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2024039858A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024039860A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039861A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076626A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
DE69531476T2 (de) 1994-09-12 2004-06-09 Lilly Industries Ltd., Basingstoke Serotonergische Modulatoren
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
UA68365C2 (en) 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1990051A1 (en) 2000-07-06 2008-11-12 Wyeth Combinations of SSRI and estrogenic agents
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
WO2002003992A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
AU2001271785A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of statins, estrogenic agents and optionally estrogens
AU2001271782A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
CN1635885A (zh) 2000-07-06 2005-07-06 惠氏公司 应用取代吲哚化合物增强一氧化氮合酶活性
AU2001271706A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
WO2002003988A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
JP2004502730A (ja) 2000-07-06 2004-01-29 ワイス ビスホスホネート、エストロゲン剤および所望によるエストロゲンの組み合わせ
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
DE60106281T2 (de) 2000-08-11 2005-02-24 Wyeth Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
SK602004A3 (en) 2001-08-11 2004-11-03 Bristol Myers Squibb Pharma Co Selective estrogen receptor modulators
WO2005080380A1 (en) 2004-02-03 2005-09-01 Eli Lilly And Company Kinase inhibitors
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
ZA200608176B (en) 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
CA2595477A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
MX348817B (es) 2009-05-27 2017-06-30 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
EA022551B1 (ru) 2010-06-10 2016-01-29 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогена и их применение
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2012084711A1 (en) 2010-12-24 2012-06-28 Msd Oss B.V. N-substituted azetidine derivatives
JP2015500346A (ja) * 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ,インク. エストロゲン受容体モジュレーターおよびその使用
KR20140103335A (ko) 2011-12-16 2014-08-26 올레마 파마슈티컬스 인코포레이티드 신규한 벤조피란 화합물, 조성물 및 이의 용도
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
SG11201509508YA (en) 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
RU2745668C2 (ru) * 2014-10-23 2021-03-30 Ой Эм Ти Джи-Мелтрон Лтд Осветительное устройство для взрывопожароопасных зон
WO2016069932A1 (en) * 2014-10-31 2016-05-06 Karsten Manufacturing Corporation Grooves of golf club heads and methods to manufacture grooves of golf club heads
JP6807841B2 (ja) * 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
HUE050466T2 (hu) 2014-12-18 2020-12-28 Hoffmann La Roche Tetrahidropirido[3,4-b]indolok mint ösztrogénreceptor-modulátorok és felhasználásuk
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な2,3−ジフェニルクロメンの誘導体
WO2016174551A1 (en) * 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
MX2018003929A (es) * 2015-10-01 2018-11-22 Olema Pharmaceuticals Inc Fármacos anti-estrogénicos tetrahidro-1h-pirido [3,4-b] indol.
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
ME03547B (me) 2016-10-24 2020-07-20 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu rаkа
SG11202100145YA (en) 2018-07-12 2021-02-25 Lilly Co Eli Selective estrogen receptor degraders
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性***受體降解劑

Also Published As

Publication number Publication date
US20240131013A1 (en) 2024-04-25
IL310489A (en) 2024-03-01
MX2021005214A (es) 2021-06-18
JP2018530549A (ja) 2018-10-18
US20210059991A1 (en) 2021-03-04
AU2023202620A1 (en) 2023-05-18
JP2023087106A (ja) 2023-06-22
WO2017059139A1 (en) 2017-04-06
CN108366996B (zh) 2021-04-09
JP2021001231A (ja) 2021-01-07
IL286518A (en) 2021-10-31
IL258363A (en) 2018-05-31
CN113248494A (zh) 2021-08-13
CN108366996A (zh) 2018-08-03
US20180289679A1 (en) 2018-10-11
DK3355884T3 (da) 2021-08-02
US10624878B2 (en) 2020-04-21
EP3355884B1 (en) 2021-04-28
EP3355884A1 (en) 2018-08-08
MX2018003929A (es) 2018-11-22
HUE055321T2 (hu) 2021-11-29
LT3355884T (lt) 2021-07-26
AU2021206861B2 (en) 2023-02-02
JP7277424B2 (ja) 2023-05-19
AU2016331065B2 (en) 2021-04-29
US20190247372A1 (en) 2019-08-15
BR112018006121A2 (pt) 2018-10-23
ES2881398T3 (es) 2021-11-29
BR122023020677A2 (pt) 2023-12-12
EP3355884A4 (en) 2019-06-05
IL286518B1 (en) 2024-02-01
SI3355884T1 (sl) 2021-11-30
HRP20211124T1 (hr) 2021-10-15
US20220370421A1 (en) 2022-11-24
PT3355884T (pt) 2021-07-26
CL2018000827A1 (es) 2018-09-28
RU2745742C1 (ru) 2021-03-31
US11672785B2 (en) 2023-06-13
KR20180071274A (ko) 2018-06-27
CY1124669T1 (el) 2022-07-22
UA122346C2 (uk) 2020-10-26
CA3000410A1 (en) 2017-04-06
US10292971B2 (en) 2019-05-21
AU2016331065A1 (en) 2018-04-26
JP6776348B2 (ja) 2020-10-28
PL3355884T3 (pl) 2021-11-29
BR112018006121B1 (pt) 2024-01-23
AU2021206861A1 (en) 2021-08-12
US11229630B2 (en) 2022-01-25
IL258363B (en) 2021-10-31
EP3912680A1 (en) 2021-11-24
RS62133B1 (sr) 2021-08-31

Similar Documents

Publication Publication Date Title
RU2021107754A (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
RU2015125307A (ru) Комбинированная терапия
JP2016501221A5 (ru)
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
JP2016530283A5 (ru)
RU2018113718A (ru) Новые соединения
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
MX2016014574A (es) El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
RU2018102963A (ru) Производные анилинпиримидина и их применения
JP2017517565A5 (ru)
EA201590221A1 (ru) Способ усовершенствованного синтеза опиоидов
RU2016148887A (ru) Пиридиновые соединения пладиенолида и способы применения
EA201590222A1 (ru) Способ усовершенствованного синтеза опиоидов
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
JP2018062523A5 (ru)